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Abstract: We have explored the possibility of using organometallic derivatives of cobalamin
as a scaffold for the delivery of the same antimalarial drug to both erythro- and hepatocytes.
This hybrid molecule approach, intended as a possible tool for the development of multi-stage
antimalarial agents, pivots on the preparation of azide-functionalized drugs which, after coupling
to the vitamin, are released with a 4-(4-ethynylphenyl)-triazole functionality. Three chloroquine
and one imidazolopiperazine derivative (based on the KAF156 structure) were selected as model
drugs. One hybrid chloroquine conjugate was extensively studied via fluorescent labelling for in vitro
and in vivo bio-distribution studies and gave proof-of-concept for the design. It showed no toxicity
in vivo (zebrafish model) as well as no hepatotoxicity, no cardiotoxicity or developmental toxicity of
the embryos. All 4-(4-ethynylphenyl)-triazole derivatives of chloroquine were equally active against
chloroquine-resistant (CQR) and chloroquine-sensitive (CQS) Plasmodium falciparum strains.
Keywords: antimalarial; prodrug; chloroquine; triazole; cobalamin; in vivo; zebrafish model
1. Introduction
Malaria is considered to be one of the most life-threatening and globally infectious diseases caused
by a single-cell parasite called Plasmodium (including P. falciparum, P. vivax, P. ovale, P. malariae). This
disease has remained one of the leading causes of morbidity and mortality over the past centuries
throughout the world. According to the World Health Organization (WHO) in 2016, there have been
about 216 million cases of malaria and 445,000 deaths worldwide [1]. A decrease of 4% annually in the
number of malaria victims over the past decade was observed, and clinical malaria cases have declined
from 2000 to 2015 in endemic parts of Africa. However, P. falciparum, the most lethal malaria species in
humans, has become resistant to the most conventional antimalarial treatments, in turn resulting in a
worldwide concern and the call for new strategies, and drugs that can act at different stages of the
parasite life cycle [2–4].
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New drug candidates are being identified as a result of the combined efforts of a global consortium
(known as the NGBS (The NGBS consortium in malaria drug discovery is a collaboration between
the Novartis Institute for Tropical Diseases (NITD), the Genomics Institute of the Novartis Research
Foundation (GNF), the Biomedical Primate Research Centre (BPRC) and the Swiss Tropical and Public
Health Institute (SwissTPH)) consortium) with the help of industry and private-public partnerships
and by leading pharmaceutical companies (like Novartis or GlaxoSmithKline) that have the capacity
for high-throughput screening of thousands of compounds [5]. These efforts have led to the chemical
optimization of DDD107498 (Figure 1), a compound with a potent antimalarial activity against multiple
life-cycle stages of the Plasmodium parasite and whose molecular target is the translation elongation
factor 2 (eEF2), essential for parasite protein synthesis [6–8]. Other strategies being pursued involve the
preparation of hybrid molecules to augment the activity profile of older drugs like chloroquine (CQ) [9].
In this approach, two different drug moieties, each with its own medicinal properties, are covalently
linked in a single hybrid molecule, which presents a dual activity. The primaquine-chloroquine
(PQ-CQ, Figure 1) hybrid reported by Lödige et al. exemplifies this approach [10]. The molecule
displays in vitro activity against both asexual and sexual P. falciparum blood stages as well as P. berghei
sporozoites and liver stages, and in vivo it is active against P. berghei liver and blood stages.
Figure 1. Molecular structures of antimalarial drugs mentioned in the introduction. JR1-3 and SN1
are the molecules designed for this study (vide infra for details). The red box indicates the structural
feature that we took as reference for the design of the compounds.
Within this context, we decided to explore the possibility of using organometallic derivatives of
cobalamin as a vector for antimalarial drugs as they were previously exploited for the targeted release
of anticancer drugs [11–13]. For our study, we decided to evaluate triazole-containing chloroquinoline
drugs, derivatized at the N-alkyl amino side chain and one imidazolopiperazine derivative based on
the KAF156 (Ganaplacide) structure (Figure 1) [14]. The latter was selected as it is a rare example of
drugs effective at the liver stage. The design of the CQ molecules was developed starting from the
reference tetrazole embedded CQ derivatives prepared by Pandey et al. (Tet-CQs in Figure 1) [15].
These derivatives are active in animal models showing between ca. 60 and 99.99% suppression of
parasitaemia on the fourth day of treatment.
In our design, the CQ ring was left untouched, as this moiety is essential for the antimalarial
activity of this class of compounds. Modifications of the CQ ring alter the pKa values of the whole
molecule thereby affecting drug uptake by the parasite digestive vacuoles and its influx/eﬄux [16].
Modification at N-alkyl amino side chain are much less detrimental for the antimalarial activity the
compounds [17]. Azoles were chosen because they are an important class of nitrogen containing
heterocyclic compounds that often improve the therapeutic and biological activity of organic drugs.
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Their addition to the side chain of 7-chloro-4-aminoquinoline was suggested as a useful strategy for
the design and development of new antimalarial agents [18]. Furthermore, tetrazole embedded CQ
derivatives inhibit hemozoin possibly via heme complexation through the azole functionality [15] and,
finally, triazole can be readily prepared via the Cu(I)-catalyzed azide-alkyne cycloaddition, a synthetic
approach applicable to vitamin B12 chemistry [19].
The use of cobalamin (B12, Cbl) as a vector of antimalarial drugs for both the hepatocytic and
erythrocytic stages rests on the consideration that vitamin B12 is transported and stored in the liver
and that naturally occurring cobalamins have antimalarial activity of their own with IC50 values
(blood stage) ranging from ca. 2–130 µM [20]. As such, they might act synergistically with other
antimalarial compounds. Among the naturally occurring Cbls, Ado-Cbl (adenosylcobalamin) is the
most active, followed by H2O-, CH3- and CN-Cbl. Furthermore, with the exception of CN-Cbl, all
derivatives are approximately forty times more effective than chloroquine in inhibiting hemozoin
formation [20]. Erythrocyte uptake ca. 20–50 pg B12/mL (ca. 0.1–0.25 µg/5 L human blood) [21]. The
uptake depends on metabolic factors, it increases with rising reticulocyte count [22] and B12 content
in red blood cells increases with levels of holoTCII (B12-bound transcobalamin II protein complex
recognized by cell for B12 uptake) [23]. Finally, P. falciparum requires nanomolar concentrations of B12
for optimal growth as a cofactor for methionine synthase [24], the only B12-dependant enzyme in the
intra-erythrocytic P. falciparum [25]. Chemaly has suggested that infected erythrocytes may uptake
cobalamin while still bound to transcobalamin II or possibly haptocorrin [20], because the parasite is
known to reactivate dormant endogenous red blood cell transporters, increase the permeability of the
erythrocytic membrane [26,27], and infected erythrocytes are able to incorporate molecules as large as
transferrin (ca. 80 kDa) [28].
2. Results and Discussion
2.1. Synthesis and Characterization
Vitamin B12 (B12, Cbl) derivatives bearing antimalarial compounds were prepared
by attaching releasable drugs at the cobalt ion via the synthetic protocol illustrated in
Figure 2. The cyanide ligand of Cbl was substituted by either 1,4-diethynylbenzene [29] or
1,4-diethynyl-2-fluorobenzene to give cobalamine-1,4-diethynylbenzene (B12-1) or the fluorinated
cobalamine-1,4-diethynyl-fluorobenzene intermediates B12-F1 and -F2 [11,30]. Following these
reactions, an absorbance at 2117 cm−1 in the IR spectrum of the species replaced the original υC≡N
frequency at 2134 cm−1 and was assigned to the cobalt-bound alkyne function. Concomitantly, the
4-diethylamino-1-methylbutylamino chain appended at the quinoline core structure of chloroquine
was replaced by a 2-azidoethyl chain (to give N-(2-azidoethyl)-7-chloroquinolin-4-amine, N3-CQ) [31].
Similarly the primary amine of KAF156 was modified to a 2-azido-acetamide function giving
2-azido-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-8,8-dimethyl-5,6-dihydroimidazo[1–a]pyrazin-
7(8H)-yl)ethan-1-one (N3-SN1, Figure 2) by using 2-azido-1,3-dimethylimidazolinium
hexafluorophosphate and triethylamne in actetonitrile. This approach rendered the molecular units
suitable for fusion via the Cu(I)-catalyzed azide-alkyne cycloaddition. Overall, following HPLC
purification, the cycloaddition reaction gave vitamin B12 derivatives (B12-JR1, 2 and 3 and B12-SN1,
Figure 2) in good yields (60–80%).
The aromatic regions of the 1H-NMR spectra of derivatives B12-JR1-3 are shown in Figure 3 (full
spectra of all molecules are found in ESI, Figures S1–S11). NMR was used with other techniques to
assess the successful synthesis of the molecules. As evident in Figure 3, the aromatic region shows
an increasing number of peaks after each modification which are related and consistent with the
addition of the alkynylated linker and the CQ drug on cobalamin (see also Figures S4–S8 in ESI). As
expected, with respect to free vitamin B12, most affected are the Co-bound dimethylbenzimidazole
peaks and the ribose signals (in the 4.5–5 ppm regions, see Figures S4–S8 in ESI) which suffer an
upfield shift after each cobalamin modification. From a stability point of view, all water-soluble
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compounds appeared photo stable in solution for at least seven days. Alongside the preparation of the
vitamin B12 derivatives, ethynylphenyl-triazolyl-chloroquine and imidazolopiperazine drugs (JR1-3
and SN1, Figure 2) were synthetized separately from the reaction of N3-CQ or N3-SN1 with either
1,4-diethynylbenzene (JR1, SN1) or 1,4-diethynyl-2-fluorobenzene (JR2 and JR3). The compounds
were purified via HPLC and isolated as TFA salts. Of the series of compounds described above, we
were able to obtain single crystals suitable for X-ray analysis of the B12-F2 precursor and the JR1
compound (namely, 7-chloro-N-(2-(4-(4-ethynylphenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine,
Figure 3). B12-F2 crystalized in the orthorhombic space group P212121 (common for Cbl derivatives).
Interestingly, the 1,4-diethynyl-2-fluorobenzene unit is found in two different conformations in the
crystal structure. In both conformations, the Co-C≡C angle is bent (167.92◦ (2) and 173.27 (3)◦) and the
triple bond length is longer than in organic alkynes (1.211 (16) Å and 1.192 (17) Å respectively), which
is consistent with previously reported acetylide cobalamins [30,32]. Compound JR1 crystalized in the
P-1triclinic space group and it is also shown in Figure 3.
Figure 2. General synthetic scheme for the synthesis of derivatives B12-JR1-JR3 and B12-SN1.
Figure 3. Left, aromatic region of the 1H-NMR spectra (D2O, 500 MHz) of CN-Cbl and of the derivatives
B12-JR1 to -JR3. Right, crystal structure of compound B12-F2 and of JR1 (thermal ellipsoids are shown
at the 50% probability).
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2.2. In Vitro Bio-Distribution and Antiplasmodial Activity
Given that the pathogenesis of the disease is based on the rosetting phenomenon [33], occurring
during the life cycle of the P. falciparum in red blood cells (RBCs) promoting the binding of parasitized
RBCs to healthy ones, our conceptual design pivots on the possibility that when attached to the
cobalamin scaffold antimalarial drugs can be delivered to both erythrocytes and hepatocytes and
intracellularly released following the natural Cbl pathway. We therefore needed to establish if the
modified vitamins could still accumulate within red blood cells to some extent. To this end, B12-JR1 was
modified at the sugar moiety with a fluorescent dye in order to track its bio-distribution both in vitro and
in vivo [34]. As shown in the synthetic protocol illustrated in Figure 4, the 5′-OH group of the Cbl ribose
was activated with 1,1′-carbonyl-di-(1,2,4-triazole) (CDT) and then reacted with an amine-terminated
Polyethylene glycol (PEG) chain to promote amide bond formation [34]. This intermediate was then
reacted with 5-carboxy-tetramethyl-rhodamine succinimidyl ester (NHS-Rhodamine) to yield the
fluorescent B12-JR1-CBC molecule. B12-JR1-CBC was then incubated within full canine blood at 37 ◦C
for 24 h in dark. After this period of time, red fluorescence was observed within erythrocytes in the
full blood smear of the blood sample (Figure 4 C–D), and we could determine that between 11–13% of
the compound associates with washed erythrocytes after 24 h incubation (Figure S21).
Figure 4. (A) Reaction steps leading to the synthesis of the green emitting B12-JR1-CBC. Conditions:
(i) CDT, 12 h, DMSO; (ii) PEG, 12 h, anhydrous DMF; (iii) NHS-rhodamine, 12 h, TEA, anhydrous
DMF. (B) Normalized excitation and emission profile of B12-JR1-CBC in a 1:1 H2O/MeOH solution.
(C,D) Fluorescent microscope images of erythrocytes within full canine blood smear incubated with
B12-JR1-CBC at 37 ◦C (GFP filter; 100 × magnification). (E) Conceptual drawing of B12-JR1-CBC
accumulation within erythrocytes. Note: as a full blood smear was made, fluorescence around red
blood cells is due to serum and/or burst erythrocytes.
Having established the intracellular erythrocyte accumulation of B12-JR1-CBC, the B12 complexes
B12-JR1–3, -SN1 and their corresponding 4-(4-ethynylphenyl)-triazole drugs JR1–3 and SN1 were
tested for their antiplasmodial activity against the erythrocyte stage of Plasmodium falciparum. All the
compounds were screened against the NF54 CQS (chloroquine-sensitive) strain of P. falciparum and
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the multidrug-resistant P. falciparum Thailand K1 strain CQR (chloroquine-resistant) isolate. Table 1
presents the data obtained from this study.
Table 1. Antiplasmodial activity of molecules against the chloroquine-sensitive (CQS) NF54 and
chloroquine-resistant (CQR) K1 strains of Plasmodium falciparum.
Compound NF54 IC50 ± SD (µM) K1 IC50 ± SD (µM) Resistance Index (RI) a
JR1 0.14 ± 0.01 0.18 ± 0.02 1.3
JR2 0.15 ± 0.01 0.16 ± 0.01 1.1
JR3 0.19 ± 0.02 0.21 ± 0.02 1.1
B12-JR1 6.27 ± 0.37 9.18 ± 0.85 1.5
B12-JR2 4.73 ± 0.32 6.02 ± 0.71 1.3
B12-JR3 9.68 ± 0.73 >15 >1.6
SN1 na b nd c nd
B12-SN1 na nd nd
CQ 0.013 ± 0.001 0.40 ± 0.04 30.8
a RI (resistance index): IC50 (CQR)/IC50 (CQS); b Not active at the tested concentration; c Not determined.
Triazole-containing quinoline JR1, JR2 and JR3 showed good activity in the sensitive strain, while
the imidazolopiperazine derivatives SN1 and B12-SN1 were inactive. B12-JR-3 exhibited moderate
activity in the NF54 strain of P. falciparum with IC50 values ca. 30–40 times higher than those of their
corresponding drugs JR1-3. The decrease in activity of the vitamin B12 derivatives, compared to
their corresponding free drugs, indicates that there are no synergistic effects between the molecular
components (i.e., B12 and JR#). Indeed, the relatively low in vitro activity of the B12 derivatives could
be attributed to low accumulation of these complexes in the digestive vacuole (DV) of the parasite
as some cobalamin compounds are less likely to accumulate in DV due to limited pH trapping [20].
Nevertheless, JR1-3, B12-JR1 and B12-JR2 are equally active against the chloroquine-resistant (CQR)
K1 strain of P. falciparum, with resistance indices very close to unity. In terms of their cytotoxicity,
molecules B12-JR1-3 showed moderate activity against human lung fibroblast MRC5 (IC50 > 70 µM)
which brings their selectivity index to the value of 10 and higher. Furthermore, B12-JR1 was screened
against the Chinese Hamster Ovarian (CHO) cell-line at a concentration ca. 400-fold its NF54 IC50
value and was found not to be toxic against mammalian cells at this dose. This confirms that these B12
complexes are selective towards the malaria parasite and because the compounds retain their activity
in the resistant strain show no cross-resistance.
2.3. Drugs Interaction with Monomeric Ferriprotoporphyrin IX (PPIX)
Chloroquine (CQ) exerts its antimalarial function by inhibiting hemozoin formation during the
critical ferriheme detoxification process of the Plasmodium parasite [35–39]. The molecule acts either
by: (a) directly complexing monomeric PPIX preventing its incorporation into the growing hemozoin
crystals [36,40–42], (b) capping the hemozoin crystal [43,44], (c) binding to PPIX via pi–pi interactions
between the its aromatic ring and the porphyrin ring [45,46], (d) shifting the haematin/µ-oxo PPIX
dimer equilibrium [40], or (e) docking onto the fastest growing crystal face [47]. To obtain an insight
into the possible mode of action of the 4-(4-ethynylphenyl)-triazole functionalized drugs, we decided
to study their interaction with strictly monomeric ferriprotoporphyrin IX via the procedure established
by Egan et al. [48,49].
Accordingly, we performed spectrophotometric titrations of the drugs into a solution of PPIX
and monitored the absorbance of the Soret band at 402 nm. Figure 5 shows the spectral changes
observed in these experiments. The decrease in absorbance of the Soret band is either indicative of a
drug-induced aggregation of PPIX, formation of pi–pi (donor acceptor) complexes or the changes reflect
drug binding to PPIX [48,49]. Our molecular design offers at least four binding possibilities to ferriheme,
but we were able to establish via DFT calculations that only the quinoline and the central triazole
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nitrogens are free of steric hindrance to support PPIX coordination (Figure S12 and S13). However,
analysis of the spectrophotometric changes revealed that: a) none of our drugs are likely forming
a 1:1 or 2:1 binding complex with PPIX as data do not fit the models of Egan et al.; b) the changes
are dissimilar from those observed upon PPIX aggregation in aqueous solution [48]; c) the end-point
spectra, after addition of a large excess of drugs, are identical to that of the µ-oxo dimer previously
reported (Figure 5C) [50]. We conclude, therefore, that JR1-3 might exert their antiplasmodial activity
by promoting ferriprotoporphyrin µ-oxo dimer formation, thereby shifting the haematin/µ-oxo PPIX
dimer equilibrium [40].
Figure 5. (A) Spectroscopic change observed in the Soret band of PPIX when it is titrated with drugs
presented in this study. (B) Variation in absorbance of PPIX at 402 nm as a function of drug concentration.
(C) Visible spectra of PPIX in 40% aqueous DMSO, pH 7.5 before (black line) and after addition of
excess drug (red line). The spectrum of the latter is identical to that of the µ-oxo dimer previously
reported. Note the peak maximum at 576 nm. (D) Density Functional Theory (DFT) optimized structure
(gas-phase) of the interaction of a protonated 4-(4-ethynylphenyl)-triazole functionalized quinoline
drug model with ferriprotoporphyrin IX µ-oxo dimer.
2.4. In Vivo Toxicity and Bio-Distribution
Based on the antiplasmodial activity and in vitro cytotoxicity results, B12-JR1 was selected for
further toxicity and distribution assessment in the zebrafish (Danio rerio) model, which proved a
useful high-throughput model for determination of the acute toxicity in drug development efforts [51].
Toxicity assessment performed in the zebrafish model (nontransgenic, wild type embryos) during a
period from 6 to 120 h post fertilization (hpf) showed that vitamin B12 (data not shown) and B12-JR1
are neither toxic (Figure 6A) nor cardiotoxic (Figure 6B) at the doses up to 150 µM. On the other
hand, the CBC-labelled molecule (B12-JR1-CBC) caused the appearance of pericardial edema and
the whole-body edema/disintegration in 25% of embryos already at a dose of 25 µM (the same side
effects were observed at 50 µM, in almost 100% of treated embryos). Notably, the toxicity of B12-JR1
appeared to be markedly higher in vitro than in vivo (IC50 of 70 µM vs LC50 > 150 µM, respectively).
According to the antiplasmodial activity and the in vivo toxicity results, B12-JR1 has a large therapeutic
window—higher than 24 for the NF54 strain (CQ-sensitive) and 16 for the K1 strain (CQ-resistant) of
P. falciparum (Table 2).
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Figure 6. Toxicity evaluation of B12-JR1 and B12-JR1-CBC in the zebrafish model over a period from 6
to 120 hpf, expressed as the LC50 values. Shown are data relative to (A) embryos survival/teratogenicity
and (B) cardiotoxicity. The liver is outlined with a dashed line.
Table 2. Therapeutic windows of B12-JR1 for NF54 strain (CQ-sensitive) and K1 strain (CQ-resistant)
of P. falciparum.
IC50 (µM) a LC50 (µM) b Ti (LC50/IC50)
NF54 K1 NF54 K1
B12-JR1 6.3 9.2 >150 >23.9 >16.3
a—in vitro data obtained in the cell-based assay; b—in vivo data obtained in the zebrafish model.
To determine the distribution and the accumulation of B12-JR1 and B12-JR1-CBC through inner
organs, transgenic Tg(fabp10:EGFP) zebrafish embryos with enhanced green fluorescent protein
(EGFP)-labelled liver were exposed to the tested compounds in a period from 106–120 hpf (the
developmental stage when the liver is highly vascularized and metabolically active). The results
showed the preferential accumulation of both compounds in the liver of treated fish when applied
in the water containing the embryos (Figure S23), as well as in the intestine due to the compounds
absorption through mouth and skin (Figure 7, Panel 1). Longer exposure (from 72–120 hpf) of zebrafish
embryos to the tested molecules resulted in higher drug accumulation in the liver, as evaluated by the
fluorescence intensity (Figure S23). Moreover, when B12-JR1 and B12-JR1-CBC were applied parenteral
by the microinjection into the blood circulation, the compounds were solely detected in the liver of
injected embryos, confirming thus their preferential accumulation in this organ. Importantly, after this
period of exposure the compounds did not affect the liver development. Because liver toxicity presents
one of the most common drawbacks of the drugs approved for the human use, the drugs synthesized
in this study were examined for the possible hepatotoxicity in vivo. The transgenic Tg(fabp:EGFP)
zebrafish embryos exposed at 72 hpf (a stage when the liver is becoming vascularized and performing
metabolic transformation of the absorbed compounds) to the synthesized drugs were evaluated for the
liver colour (a possible necrosis sign), size, fluorescence and the liver area index (the body area/liver
area ratio). These are all parameters commonly used for hepatotoxicity evaluation and to follow the
effect of applied therapies on the liver function.
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Figure 7. Bio-distribution and toxicity evaluation of B12-JR1 and B12-JR1-CBC in the 120-hpf old
transgenic Tg(fabp10:EGFP) zebrafish embryo with fluorescently labelled liver. Panel 1 (top left). Top:
accumulation of B12-JR1 (150 µM) in the liver applied at 106 hpf in the embryo water. (A) Embryo
imaged by a fluorescent microscope with a filter enabling only EGFP-labelled liver visualization.
(B) Embryo imaged with a filter enabling B12-JR1 visualization, but not EGFP-labelled liver. (C) Merged
images A and B. Middle: accumulation of B12-JR1-CBC (20 µM) in the liver applied at 106 hpf in
the embryo water. (D) Embryo imaged upon a filter enabling only EGFP-labelled liver visualization.
(E) Embryo imaged with a filter enabling only B12-JR1 visualization, and (F) merged Tg(fabp10:EGFP)
and B12-JR1-CBC fluorescent signals in the same embryo. Bottom: an accumulation of B12-JR1-CBC
(47.8 µg per an embryo, corresponding to 20 µM dose) in the liver microinjected (parenteral use) into
embryo’s circulation at 106 hpf. Arrows in the panel 1 indicate the liver position within embryos
body. Panel 2 (top right): distribution of B12-JR1 (150 µM) within the 120-hpf old embryos when
applied at 6 hpf (the liver-free stage, A) or 72 hpf (the stage with functional liver, B). Lateral views
(C and D) of the 120-hpf embryo with an overlay. Overlay outlines the pharynx (Ph), esophagus (E),
liver (L), gallbladder (G), pancreas (P), swimmbladder (SB), and intestine (I). * marks intestinal lumen.
Panel 3 (bottom). Hepatotoxicity evaluation in the transgenic Tg(fabp10:EGFP) zebrafish embryos with
EGFP-labelled liver after the embryos exposure to the tested compounds in a period from 72–120 hpf
(A). The liver area index was assessed in 120-h old zebrafish embryos (B) and indicated no changes in
the treated groups compared to the DMSO-treated (control) one (n = 15).
The results show that both compounds, applied at the 150 µM for B12-JR1 and 20 µM for
B12-JR1-CBC, caused no changes in the liver size and fluorescence (Figure 7, Panel 3), and did not affect
the liver area index. In addition, liver colour and yolk consumption in the treated fish, as additional
specific phenotypic endpoints of hepatotoxicity, did not change in comparison to that of the control
embryos (Figure 7, Panel 2), even when the embryos were exposed earlier at the 6 hpf stage (Figure 6B).
Overall, the results indicate that B12-JR1 is not hepatotoxic, at least, at a dose 16–24 higher than the one
active against Plasmodium strains. Taken together, the results indicate that B12-JR1 and B12-JR1-CBC
indeed accumulate in the liver, and cause no hepatotoxicity, no cardiotoxicity or developmental toxicity
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at concentrations efficient against P. falciparum. This is of particular relevance in the therapy against
the CQ-resistant malarial strains, since chloroquine, the most frequently used antiplasmodial drug, is
very hepatotoxic already at 30 µM [52], while B12-JR1 is not at 150 µM.
3. Materials and Methods
3.1. General Experimental Details
All chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA) and used without
further purification. HPLC analyses were performed on a Merck-Hitachi L7000 (Hitachi, Ltd.,
Tokyo, Japan). The analytical separations were conducted on a Macherey–Nagel Nucleodur
PolarTec column (Macherey–Nagel AG, Oensingen, Switzerland, 5 µm particle size, 110 Å pore
size, 250 × 3 mm). The preparative separations were conducted on a Macherey–Nagel Nucleodur
C18 HTec column (Macherey–Nagel AG, Oensingen, Switzerland, 5 µm particle size, 110 Å pore
size, 250 × 21 mm). HPLC solvents were for the system 1: aqueous trifluoroacetic acid 0.1%
(A) and THF (B). HPLC solvents were for the system 2: aqueous trifluoroacetic acid 0.1% (A)
and methanol (B). Using system 1, the compounds were separated using the following gradient:
0–5 min (75% solvent A), 5–35 (75% solvent A → 35% solvent A), 35–45 min (100% solvent B).
Using system 2, the compounds were separated using the following gradient: 0–5 min (75% solvent
A), 5–35 (75% solvent A → 0% solvent A), 35–45 min (100% solvent B). The flow rate was set
to 0.5 mL/min for analytical separations and 5 mL/min for the preparative ones. The eluting
bands were detected at 320 nm. The preparative plates used for the separation of the compounds
7-chloro-N-(2-(4-(4-ethynyl-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine (JR2) and
7-chloro-N-(2-(4-(4-ethynyl-2-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine (JR3) were
purchased from Sigma-Aldrich (20 cm × 20 cm, 2 mm). NMR analyses were recorded on a Bruker
Avance III 500 MHz. The corresponding 1H and 13C chemical shifts are reported relative to residual
solvent protons and carbons.
3.2. Instrumentation
HPLC analyses were performed on a Merck-Hitachi L7000 (Hitachi, Ltd., Tokyo, Japan). High
resolution ESI-MS was performed on a Bruker FTMS 4.7-T Apex II (Bruker Daltonics GmbH, Fällanden,
Switzerland). NMR spectra were recorded on a Bruker Avance III 500 MHz (Bruker Daltonics GmbH,
Fällanden, Switzerland). UV/Vis spectra were recorded on a Jasco V-730 (JASCO Deutschland GmbH,
Pfungstadt, Germany) and the emission on a spectrofluorometer FS5 (Edinburgh Instruments Ltd.,
Livingston, UK). Titration experiments were performed as described by Egan et al. [49]. with
the only exception that PBS (Phosphate-Buffered Saline) (1X, pH 7.4) was used instead of the
N-[2-hydroxethyl]piperazine-N′-[2-ethane sulphonate] (HEPES) buffer. Crystallographic data were
recorded on a SuperNova, Dual, Cu at zero, AtlasS2 diffractometer (Agilent Technologies XRD
Products, Santa Clara, CA, USA). For biological studies, the extent of MTT reduction was measured
spectrophotometrically via a Tecan Infinite 200 Pro multiplate reader (Tecan Group Ltd., Männedorf,
Switzerland). Microscopy and fluorescent images were recorded with an inverted microscope (CKX41;
Olympus, Tokyo, Japan) and a fluorescent microscope (Olympus BX51, Applied Imaging Corp., San
Jose, CA, USA) respectively.
3.3. Computational Details
Geometry optimizations as well as frequency calculations (gas phase), were performed at the
Density Functional level of theory with the Gaussian09 program package (AMD64, Gaussian Inc.,
Wallingford, CT, USA) using the hybrid B3LYP [53] or M06 [54,55] functional in conjunction with the
LanL2DZ basis set [56–58]. Pure basis functions (5d, 7f) were used in all calculations. Geometries
were optimized without symmetry restrictions. The nature of the stationary points was checked by
computing vibrational frequencies in order to verify true minima.
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3.4. General Synthesis Procedures
Synthesis procedures for 7-chloro-N-(2-(4-(4-ethynylphenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-
4-amine (compound JR1), a mixture of N-(2-azidoethyl)-7-chloroquinolin-4-amine (N3-CQ) (100 mg,
0.4 mmol, 1 eq.), 1,4-diethynylbenzene (60.5 mg, 0.5 mmol, 1.2 eq.) and tris(benzyltriazolylmethyl)amine
(TBTA, 2 mg, 0,004 mmol, 1 mol-%) was dissolved in DMF (0.7 mL). To this solution was added a water
mixture (0.3 mL) of CuSO4·5H2O (1 mg, 0,004 mmol, 1 mol-%) and sodium ascorbate (8 mg, 0,04 mmol,
0,1 eq.). The compounds were reacted overnight with stirring at room temperature. The compounds
7-chloro-N-(2-(4-(4-ethynyl-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine (JR2) and
7-chloro-N-(2-(4-(4-ethynyl-2-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine (JR3) were
prepared similarly by replacing the 1,4-diethynylbenzene with 1,4-diethynyl-2-fluorobenzene (72 mg,
0.5 mmol, 1.2 eq.). Following the reaction, the solution containing JR1 was filtered and purified by
HPLC (system 2). The crude reaction containing both JR2 and JR3 compounds was also filtered and
the filtrate freeze-dried. The remaining solid was redissolved in the minimal amount of DMF (0.2 mL)
and completed with DCM/MeOH (0.4 mL, 9:1). The isomers were separated on a preparative TLC
plate using DCM/MeOH (9:1) as eluent.
7-Chloro-N-(2-(4-(4-ethynylphenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine (JR1): yield 123 mg
(0.033 mmol, 83%). 1H NMR (500 MHz, DMF-[d7]): δ = 9.68 (t, J = 5.6 Hz, 1H), 8.82 (s, 1H), 8.70 (d,
J = 6.9 Hz, 1H), 8.60 (d, J = 9.0 Hz, 1H), 8.23 (d, J = 2.0 Hz, 1H), 8.03 (s, 1H), 7.89 (d, J = 8.45 Hz, 2H),
7.70 (dd, J = 7.76 Hz, 1H), 7.58 (dd, J = 8.35 Hz, 1H), 7.16 (d, J = 7Hz, 1H), 4.97 (t, J = 5.7 Hz, 2H), 4.31
(dd, J = 5.3, 5.8 Hz, 2H), 4.20 (s, 1H) ppm; 13C NMR (125 MHz, CDCl3-[d1]): δ= 165.4, 157.1, 146.4,
145.4, 141.1, 139.6, 135.8, 135.3, 128.4, 126.3, 124.5, 122.4, 121.6, 117.4, 113.0, 110.5, 100.1, 86.9, 77.8, 49.5,
44.5 ppm; HR-ESI-MS (ESI+): [M + H]+ = 374.1176, calculated for C21H17N5Cl1 = 374.1167.
7-Chloro-N-(2-(4-(4-ethynyl-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine (JR2): yield
67 mg (0.017 mmol, 43%). 1H NMR (500 MHz, DMF-[d7]): δ = 9.59 (t, J = 5.86 Hz, 1H), 8.88 (s, 1H), 8.74
(d, J = 6.9 Hz, 1H), 8.56 (d, J = 9.0 Hz, 1H), 8.19 (d, J = 2.0 Hz, 1H), 7.79 (dd, J = 2.0, 9.0 Hz, 1H), 7.75 (t,
J = 1.45 Hz, 1H), 7.73 (dd, J = 1.45, 4.5 Hz, 1H), 7.66 (t, J = 7.7 Hz, 1H), 7.16 (d, J = 6.8Hz, 1H), 4.98
(t, J = 6.15 Hz, 2H), 4.54 (s, 1H), 4.31 (dd, J = 5.5, 5.8 Hz, 2H) ppm; 13C NMR (125 MHz, CDCl3-[d1]):
δ = 156.3, 146.5, 144.3, 140.0, 138.8, 132.8 (2C), 132.0, 127.5, 125.6 (3C), 123.0, 121.8, 120.4, 116.5, 99.3, 83.7,
80.6, 48.5, 43.8 ppm; HR-ESI-MS (ESI+): [M + H]+ = 392.1067, calculated for C21H16N5Cl1 = 392.1072.
7-Chloro-N-(2-(4-(4-ethynyl-2-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine (JR3): yield
62 mg (0.16 mmol, 40%). 1H NMR (500 MHz, DMF-[d7]): δ = 9.68 (t, J = 5.96 Hz, 1H), 8.75 (d, J =
7.14 Hz, 1H), 8.68 (d, J = 3.8 Hz, 1H), 8.60 (d, J = 9.2 Hz, 1H), 8.21 (t, J = 8.0 Hz, 1H), 8.20 (d, J = 2.0,
1H), 7.81 (dd, J = 2.0, 9.14 Hz, 1H), 7.49 (dd, J = 1.55, 3.8 Hz, 1H), 7.48 (dd, J = 1.35, 7.05 Hz, 1H), 7.20
(d, J = 7.0 Hz, 1H), 5.02 (t, J = 5.8 Hz, 2H), 4.35 (s, 1H), 4.35 (dd, J = 5.5, 5.8 Hz, 2H) ppm; 13C NMR
(125 MHz, CDCl3-[d1]): δ= 160.0, 158.5, 157.3, 144.9, 140.7, 140.5, 139.8, 129.8, 128.6, 126.4, 126.1, 124.1,
121.0, 120.3, 117.2, 100.2, 83.2, 82.7, 49.4, 44.6 ppm; HR-ESI-MS (ESI+): [M + H]+ = 392.1067, calculated
for C21H16N5Cl1 = 392.1072
The synthesis of the derivatives cobalamine-1,4-diethynylbenzene (B12-1), cobalamine-1,4-
diethynyl-1-fluorobenzene (B12-F1) and cobalamine-1,4-diethynyl-2-fluorobenzene (B12-F2) was
adapted from the reference 29. A mixture of cyanocobalamin (60 mg, 0.04 mmol, 1 eq.), CuAcO
(7 mg, 0.004 mmol, 0.1 eq.) and the respective alkynes (0.4 mmol, 10 eq.) in DMA (10 mL)
was stirred until dissolution. DBU (0.03 mL, 0.21 mmol, 5 eq.) was added and the solutions
allowed to react at room temperature for 4 h. The respective crudes were precipitated by dropwise
addition to the stirred solutions of diethyl ether/CH2Cl2 (150 mL, 1:1). The residues were dissolved
in a mixture of CH3OH and water (1.5 mL, 1:1), filtered again and purified by preparative
HPLC using system 1 for the mixture B12-F1 and B12-F2 and system 2 for B12-1. The eluting
bands containing the desired products were isolated and lyophilized. The antimalarial B12 were
similarly prepared by Cu(I)-catalyzed azide-alkyne cycloaddition reaction. For the compound
cobalamin-7-chloro-N-(2-(4-(4-ethynylphenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine (B12-JR1),
a mixture of N3-CQ (10 mg, 0.04 mmol, 1 eq.) and TBTA (1 mg, 0,002 mmol, 5 mol-%) was dissolved
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in DMF (0.6 mL). To this solution was added a water mixture (0.4 mL) of B12-1 (60 mg, 0.04 mmol,
1 eq.) CuSO4·5H2O (0.5 mg, 0,002 mmol, 5 mol-%) and sodium ascorbate (0.8 mg, 0,004 mmol, 0,1 eq.).
The compounds were reacted overnight with stirring at room temperature. For the compounds
cobalamin-7-chloro-N-(2-(4-(4-ethynyl-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine
(B12-JR2) and cobalamin-7-chloro-N-(2-(4-(4-ethynyl-2-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)
quinolin-4-amine (B12-JR3), the same procedure was repeated but cyanocobalamin was replaced by the
respective B12 precursors, B12-F1 and B12-F2 respectively (59 mg, 0.04 mmol, 1 eq.). The residues were
dissolved in a mixture of CH3OH and water (1.5 mL, 1:1), filtered again and purified by preparative
HPLC using system 2 for both B12-JR2 and B12-JR3. The eluting bands containing the desired products
were isolated and lyophilized.
Cobalamine-1,4-diethynyl-1-fluorobenzene (B12-F1): Yield 24.2 mg (0,017 mmol, 41%). 1H NMR
(500 MHz, MeOD-[d4]): δ = 7.24 (s, 2H), 7.02 (s, 1H), 7.01 (d, J = 7.9 Hz, 1H), 6.81 (d, J = 7.9 Hz, 1H),
6.65 (s, 1H), 6.28 (d, J = 3.12 Hz, 1H), 6.02 (s, 1H), 4.73–4.65 (m, 1H), 4.63 (d, J = 8.25 Hz, 1H), 4.44 (d,
J = 11.3 Hz, 1H), 4.39–4.31 (m, 1H), 4.22 (d, J = 3.6 Hz, 1H), 4.15–4.09 (m, 1H), 3.94 (dd, J = 3.2, 12.7
Hz, 1H), 3.78 (dd, J = 4.3, 12.7 Hz, 1H), 3.69 (d, J = 14.0 Hz, 1H), 3.64 (q, J = 5Hz, 1H), 3.56 (s, 1H),
3.24 (d, J = 10.0 Hz, 1H), 2.92–2.82 (m, 2H), 2.65–2.59 (m, 16H), 2.57 (d, J = 4.88 Hz, 6H), 2.56–2.50 (m,
4H), 2.35 (s, 1H), 2.30 (d, J = 3 Hz, 3H), 2.28–2.19 (m, 2H), 2.13–1.91 (m, 6H), 1.87 (s, 3H), 1.86–1.70
(m, 3H), 1.48 (s, 3H), 1.41–1.38 (m, 1H), 1.37 (m, 3H), 1.35–1.32 (m, 1H), 1.27 (d, J = 6.24 Hz, 3H),
1.24–1.16 (m, 1H), 1.14 (s, 3H), 0.52 (s, 3H) ppm; HR-ESI-MS (ESI+): [M + H]+ = 1472.5989, calculated
for C72H93N13O14Co1P1F1 = 1472.6013
Cobalamine-1,4-diethynyl-2-fluorobenzene (B12-F2): Yield 22.5 mg (0,015 mmol, 38%). 1H NMR
(500 MHz, MeOD-[d4]): δ = 7.24 (d, J = 4.32 Hz, 1H), 7.20 (t, J = 7.82 Hz, 1h), 6.64 (ps, 1H), 6.62 (d,
J = 7.17 Hz, 1H), 6.56 (d, J = 10.4 Hz, 1H), 6.28 (d, J = 3.12 Hz, 1H), 6.02 (s, 1H), 4.73–4.65 (m, 1H),
4.63 (d, J = 8.25 Hz, 1H), 4.44 (d, J = 11.3 Hz, 1H), 4.39–4.31 (m, 1H), 4.22 (d, J = 3.6 Hz, 1H), 4.15–4.09
(m, 1H), 3.94 (dd, J = 3.2, 12.7 Hz, 1H), 3.78 (dd, J = 4.3, 12.7 Hz, 1H), 3.69 (d, J = 14.0 Hz, 1H), 3.64
(q, J = 5Hz, 1H), 3.56 (s, 1H), 3.24 (d, J = 10.0 Hz, 1H), 2.92–2.82 (m, 2H), 2.65–2.59 (m, 16H), 2.57 (d,
J = 4.88 Hz, 6H), 2.56–2.50 (m, 4H), 2.35 (s, 1H), 2.30 (d, J = 3 Hz, 3H), 2.28–2.19 (m, 2H), 2.13–1.91
(m, 6H), 1.87 (s, 3H), 1.86–1.70 (m, 3H), 1.48 (s, 3H), 1.41–1.38 (m, 1H), 1.37 (m, 3H), 1.35–1.32 (m,
1H), 1.27 (d, J = 6.24 Hz, 3H), 1.24–1.16 (m, 1H), 1.14 (s, 3H), 0.52 (s, 3H) ppm; HR-ESI-MS (ESI+):
[M + H]+ = 1472.5989, calculated for C72H93N13O14Co1P1F1 = 1472.6013
Cobalamin-7-chloro-N-(2-(4-(4-ethynylphenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine (B12-JR1):
Yield 51.6 mg (0,03 mmol, 75%). 1H NMR (500 MHz, D2O-[d1]): δ = 8.10 (s, 1H), 8.08 (d, J = 7.30 Hz,
1H), 7.95 (d, J = 9.1 Hz, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.39 (dd, J = 1.9, 9.13 Hz, 1H), 7.26 (d, J = 1.45
Hz, 2H), 7.23 (s, 1H), 7.10 (s, 1H), 6.89 (d, J = 8.3 Hz, 2H), 6.54 (s, 1H), 6.48 (d, J = 7.25 Hz, 1H), 6.35
(d, J = 2.91 Hz, 1H), 5.94 (s, 1H), 4.76–4.70 (m, 2H), 4.36–4.24 (m, 4H), 4.18–4.12 (m, 2H), 4.11–4.04 (m,
2H), 4.94 (d, J = 12.9 Hz, 1H), 3.77 (dd, J = 3.9, 12.9 Hz, 1H), 3.59 (d, J = 14.7 Hz, 1H), 3.20 (dd, J = 5.0,
11.0 Hz, 1H), 3.04 (d, J = 10.0 Hz, 1H), 2.96 (dd, J = 9.13, 14.3 Hz, 1H), 2.76–2.45 (m, 13H), 2.46–2.32 (m,
6H), 2.26 (s, 6H), 2.20–2.07 (m, 3H), 2.06–1.90 (m, 5H), 1.86 (s, 3H), 1.82–1.69 (m, 3H), 1.38 (s, 3H), 1.36 (s,
3H), 1.26 (d, J = 6.3 Hz, 3H), 1.18 (s, 3H), 1.13–1.01 (m, 2H), 0.97 (s, 3H), 0.46 (s, 3H) ppm; HR-ESI-MS
(ESI+): [M + 2H]2+ = 851.3401, calculated for C83H105N18O14Co1P1Cl1 (2+) = 851.3402.
Cobalamin-7-chloro-N-(2-(4-(4-ethynyl-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine
(B12-JR2): Yield 41.7 mg (0,024 mmol, 60%). 1H NMR (500 MHz, D2O-[d1]): δ = 8.10 (s, 1H), 8.09 (d,
J = 6.0 Hz, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.54 (d, J = 1.94 Hz, 1H), 7.48 (dd, J = 1.9, 9.3 Hz, 1H), 7.28 (s,
1H), 7.14 (s, 1H), 7.01 (s, 1H), 6.95 (d, J = 3.0 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 6.56 (s, 1H), 6.48 (d,
J = 7.3 Hz, 1H), 6.37 (d, J = 3.13 Hz, 1H), 6.0 (s, 1H), 4.76–4.70 (m, 2H), 4.36–4.24 (m, 4H), 4.18–4.12
(m, 2H), 4.11–4.04 (m, 2H), 4.94 (d, J = 12.9 Hz, 1H), 3.77 (dd, J = 3.9, 12.9 Hz, 1H), 3.59 (d, J = 14.7
Hz, 1H), 3.20 (dd, J = 5.0, 11.0 Hz, 1H), 3.04 (d, J = 10.0 Hz, 1H), 2.96 (dd, J = 9.13, 14.3 Hz, 1H),
2.76–2.45 (m, 13H), 2.46–2.32 (m, 6H), 2.26 (s, 6H), 2.20–2.07 (m, 3H), 2.06–1.90 (m, 5H), 1.86 (s, 3H),
1.82–1.69 (m, 3H), 1.38 (s, 3H), 1.36 (s, 3H), 1.26 (d, J = 6.3 Hz, 3H), 1.18 (s, 3H), 1.13–1.01 (m, 2H),
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0.97 (s, 3H), 0.38 (s, 3H) ppm; HR-ESI-MS (ESI+): [M + Na]+ = 1741.6457, calculated for C83H102
N18O14Co1P1F1Na1 = 1741.6457.
Cobalamin-7-chloro-N-(2-(4-(4-ethynyl-2-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)quinolin-4-amine
(B12-JR3): Yield 48.8 mg (0.028 mmol, 75%). 1H NMR (500 MHz, D2O-[d1]): δ = 8.00 (d, J = 7.0 H 1H),
7.97 (s, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.31 (ps, 1H), 7.17 (s, 1H), 7.09 (d, J = 8.6 Hz, 1H), 7.00 (s, 1H), 6.63
(d, J = 8.09 Hz, 1H), 6.45 (d, J = 9.6 Hz, 1H), 6.43 (s, 1H), 6.38 (d, J = 6.8 Hz, 1H), 6.26 (d, J = 2.8 Hz, 1H),
5.8 (s, 1H), 4.76–4.70 (m, 2H), 4.36–4.24 (m, 4H), 4.18–4.12 (m, 2H), 4.11–4.04 (m, 2H), 4.94 (d, J = 12.9
Hz, 1H), 3.77 (dd, J = 3.9, 12.9 Hz, 1H), 3.59 (d, J = 14.7 Hz, 1H), 3.20 (dd, J = 5.0, 11.0 Hz, 1H), 3.04 (d,
J = 10.0 Hz, 1H), 2.96 (dd, J = 9.13, 14.3 Hz, 1H), 2.76–2.45 (m, 13H), 2.46–2.32 (m, 6H), 2.26 (s, 6H),
2.20–2.07 (m, 3H), 2.06–1.90 (m, 5H), 1.86 (s, 3H), 1.82–1.69 (m, 3H), 1.38 (s, 3H), 1.28 (s, 3H), 1.24 (s,
3H), 1.17 (d, J = 6.23 Hz, 3H), 1.03 (s, 1H), 0.78 (s, 3H), 0.36 (s, 3H) ppm; HR-ESI-MS (ESI+): [M + Na]+
= 1741.6457, calculated for C83H102 N18O14Co1P1F1Na1 = 1741.6457.
Synthesis of 2-azido-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-8,8-dimethyl-5,6-dihydroimidazo
[1,2-a]pyrazin-7(8H)-yl)ethan-1-one (N3-SN1): To the solution of KAF156 (100 mg, 0.024 mmol, 1.0 eq)
in dry acetonitrile (10 mL) under argon, 2-azido-1,3-dimethylimidazolinium hexafluorophosphate
(90 mg, 0.031 mmol, 1.3 eq) and trimethylamine andydruos (180 µL,0.121 mmol, 5.0 eq) were added.
The mixture was then heated to 30 ◦C and stirred for 4 h. After the reaction completion, the solvent
was evaporated, DCM (20 mL) and water (20 mL) were added to the residue and the two phases were
separated. The aqueous phase was extracted with 2 × 20 mL of CH2Cl2. The combined organic layers
were washed with brine (20 mL), separated and dried over Na2SO4. The mixture was filtered and
the solvent was removed under reduced pressure. The crude product was purified by flash column
chromatography to afford compound N3-SN1 as a white solid. Yield: 85 mg (0.194 mmol, 80%). 1H
NMR (400 MHz, MeOD-[d4]): δ = 7.73 (dd, J = 5.2, 5.92 Hz, 2H), 7.04 (dd, J = 8.68 Hz, 2H), 6.91 (dd,
J = 8.96 Hz, 2H), 6.57 (dd, J = 4.32, 6.8 Hz, 2H), 4.17 (s, 2H), 3.84 (t, J = 5.36, 2H), 3.68 (t, J = 5.76, 2H),
1.97 (s, 6H), = 5.8 HR-ESI-MS (ESI+): [M + H]+ = 437.47, calculated for C22H21F2N7O = 437.17.
Synthesis of 2-(4-(4-ethynylphenyl)-1H-1,2,3-triazol-1-yl)-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)
amino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethan-1-one (SN1): A mixture of
N3-SN1 (85 mg, 0.194 mmol, 1 eq.), 1,4-diethynylbenzene (29.40 mg, 0.233 mmol, 1.2 eq.) and Et3N
(7.87 mg, 0.077 mmol, 40 mol-%) was dissolved in DMF (1 mL). CuI (3.70 mg, 0.019 mmol, 10 mol-%)
was added to this solution. The compounds were reacted overnight with stirring at room temperature.
After the reaction completion, brine (20 mL) and dichloromatane (20 mL) were added to the solution.
The aqueous phase was extracted with 2 × 20 mL of CH2Cl2. The combined organic layers were
washed with brine (20 mL) and the organic layer separated and dried over Na2SO4. Then, the mixture
was filtered and finally CH2Cl2 was removed under reduced pressure. The crude product was purified
by flash column chromatography to afford compound SN1 as a white solid. Yield: 93 mg (0.165 mmol,
85%). 1H NMR (400 MHz, (CD3)2CO-[d6]): δ = 8.22 (s, 2H), 7.78 (m, 4H), 7.43 (d, J = 8.4Hz, 2H), 6.92
(d, J = 8.6 2H), 6.82 (dd, J = 8.56 2H), 6.56 (dd, J = 4.48, 8.92 Hz 2H), 5.52 (s, 2H), 3.89 (t, J = 5.6 Hz, 2H),
3.85 (t, J = 5.40 Hz, 2H), 3.55 (s, 1H), 1.77 (s, 6H); HR-ESI-MS (ESI+): [M + H]+ = 564.23, calculated for
C32H28F2N7O = 564.23.
Synthesis of Cobalamin-2-(4-(4-ethynylphenyl)-1H-1,2,3-triazol-1-yl)-1-(2-(4-fluorophenyl)-3-
((4-fluorophenyl)amino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethan-1-one
(B12-SN1): a mixture of N3-SN1 (50 mg, 0.114 mmol, 1 eq.) and TBTA (3.03 mg, 0,005 mmol, 5 mol-%)
was dissolved in DMF (1 mL). To this solution a water mixture (0.4 mL) of B12-1 (166 mg, 0.114 mmol,
1 eq.) CuSO4·5H2O (1.42 mg, 0,005 mmol, 5 mol-%) and sodium ascorbate (2.26 mg, 0,011 mmol,
0.1 eq.) was added. The mixture stirred overnight at room temperature. The residues were dissolved
in a mixture of CH3OH and water (1.5 mL, 1:1), filtered again and purified by preparative HPLC using.
The eluting bands containing the desired products were isolated and lyophilized. The pure product
(B12-SN1) was obtained as a red solid. Yield: 116.70 mg (0.080 mmol, 70%); 1H NMR (400 MHz,
D2O-[d1]): δ = 8.19 (s, 1H), 7.73 (dd, J = 5.4, 14.4 Hz, 2H), 7.57 (d, J = 8.3 Hz, 1H), 7.25 (s, 2H), 7.04
(t, J = 6.84 Hz, 1H), 6.92 (dd, J = 8.4 14.96 Hz, 4H), 6.66 (s, 1H), 6.58 (dd, J = 4.4, 4.52 2H), 6.23 (d,
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J = 3.12 Hz, 1H), 6.02 (s, 1H), 5.56 (d, J = 7.0 Hz, 1H), 4.76–4.60 (m, 3H), 4.45 (d, J = 11.48, 1H), 4.4–4.30
(m, 1H), 4.22 (t, J = 3.6, 1H), 4.16–4.10 (m, 1H), 3.95 (dd, J = 1.62, 11.02 Hz, 1H), 3.79 (dd, J = 4.36,
10.42 Hz, 1H), 3.69 (d, J = 13.88 Hz, 1H), 3.59 (dd, J = 4.96, 8.16 Hz, 1H), 3.26 (d, J = 9.76 Hz, 1H),
2.87 (m, 2H), 2.66–2.2 (m, 13H), 2.50–2.43 (m, 3H), 2.37 (d, J = 13.2, 1H), 2.3 (d, J = 4.6, 6H), 2.27–2.21
(m, 1H), 1.95 (s, 6H), 1.89 (s, 3H), 1.85–1.71 (m, 2H), 1.49 (S, 3H), 1.38 (s, 3H), 1.34 (s, 3H), 1.27 (d,
J = 6.3 Hz, 3H), 1.17 (s, 3H), 0.53 (s, 3H) ppm; HR-ESI-MS (ESI+): [M + 2H]2+ = 945.3402, calculated for
[C95H115CoF2N19O15P]2+ = 945.9.
3.5. In Vitro Cytotoxicity Assay
B12-JR1 was screened for in vitro cytotoxicity against the Chinese Hamster Ovarian (CHO) cell-line
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assay [59]. The test
sample was prepared to a 20 mg mL−1 stock solution in 100% DMSO and tested in triplicate. Stock
solutions were stored at −20 ◦C. Further dilutions were prepared in complete medium on the day of
the experiment. Samples were tested as a suspension if not completely dissolved. Emetine was used as
the reference drug in all experiments. The initial concentration of emetine was 100 µg mL−1, which
was diluted in complete medium with 10-fold dilutions to give 6 concentrations, the lowest being
0.001 µg mL−1. The same dilution technique was applied to all test samples. The highest concentration
of solvent to which the cells were exposed to have no measurable effect on the cell viability. The 50%
inhibitory concentration (IC50) values were obtained from full dose-response curves, using a non-linear
dose-response curve fitting analysis via GraphPad Prism v.5 software. Furthermore, the cytotoxicity in
terms of the antiproliferative effect of B12-JR1, B12-JR2 and B12-JR3 were similarly evaluated by the
MTT assay. The assay was carried out using human lung fibroblasts (MRC5) cell line after 48 h of cell
incubation in the medium, containing compounds at concentrations ranging from 5 to 200 µM. Briefly,
MRC5 cells were maintained in RPMI-1640 medium supplemented with 100 µg/mL streptomycin,
100 U/mL penicillin and 10% (v/v) fetal bovine serum (FBS) (Gibco) as a monolayer (1 × 104 cells
per well). All cell lines were grown in humidified atmosphere of 95% air and 5% CO2 at 37 ◦C. The
MTT assay was performed two times in four replicates. The extent of MTT reduction was measured
spectrophotometrically at 540 nm using a Tecan Infinite 200 Pro multiplate reader (Tecan Group Ltd.,
Männedorf, Switzerland), and the cell survival was expressed as percentage of the control (untreated
cells). Cytotoxicity was expressed as the concentration of the compound inhibiting cell growth by
50% (IC50) in comparison to untreated control. The results were expressed as mean values ± standard
deviation (SD) and analysed using Student’s t-test at a threshold level of p = 0.05. Statistical analysis
was carried out using SPSS 20 (SPSS Inc., Chicago, IL, USA) software. All experiments were conducted
in at least three replicates.
3.6. In Vitro Antiplasmodial Assay
The test samples were tested in triplicate against the chloroquine-sensitive (CQS) strain of
Plasmodium falciparum (NF54) and the CQ-resistant isolate (K1). Continuous in vitro cultures of asexual
erythrocyte stages of P. falciparum were maintained using a modified method by Trager and Jensen [60].
Quantitative assessment of the antiplasmodial activity in vitro was determined via the parasite lactate
dehydrogenase assay using a modified method described by Makler [61]. The test samples were
prepared to a 20 mg/mL stock solution in 100% DMSO and sonicated to enhance solubility. Samples
were tested as a suspension if not completely dissolved. Stock solutions were stored at −20 ◦C. Further
dilutions were prepared on the day of the experiment. Chloroquine (CQ) was used as the reference
drug in all experiments. A full dose-response was performed for all compounds to determine the
concentration inhibiting 50% of parasite growth (IC50 value). The vitamin B12 complexes were tested
at starting concentrations up to 50 µg/ mL, which was then serially diluted 2-fold in complete medium
to give 10 concentrations. The ligands were tested at a starting concentration of 10 µg/mL, which was
serially diluted 2-fold in complete medium to give 10 concentrations. CQ was tested at a starting
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concentration of 1 µg/mL. The IC50 values were obtained using a non-linear dose-response curve fitting
analysis via Graph Pad Prism v.5.0 software (GraphPad Software Inc., San Diego, CA, USA).
3.7. In Vitro Blood Assays
B12-JR1-CBC was used to study in vitro bio-distribution in blood using both whole-blood and
washed red blood cells. Blood was collected from a healthy dog with the consent of owner into
BD Vacutainer® Plus plastic citrate tube (2 mL; haematocrit value of 40, Vetlab Animal Diagnostic
Laboratory, Belgrade, Serbia; http://www.vetlab.rs/) and used immediately as a whole-blood sample
and for the red blood cells (RBC) preparation. The platelet rich plasma and buffy coat were discarded
after centrifugation (370× g, 10 min). The erythrocytes were then washed in 10 times their volume of
phosphate-buffered saline (PBS) and resuspended in isotonic PBS. The haemoglobin concentration
was adjusted to 2 g/100 mL. To the whole-blood and to the RBC suspension B12-JR1-CBC (20 µM
final concentration) was added. The final incubation volume was 1 mL and the tubes were shaken
on rocking platform at 37 ◦C for 24 h in dark. At different incubation periods (30 min, 2 h, 8 h, 12 h
and 24 h) 5 µL of the whole sample was spread on the microscopic slide for the direct examination
(fluorescence microscope Olympus BX51, Applied Imaging Corp., San Jose, CA, United States; Texas
Red filter), while 100 µL of RBC incubation mixture was transferred into 0.5 mL Eppendorf tube,
centrifuged briefly (370× g, 1 min) and 50 µL sample of the supernatant diluted 10-fold in PBS and
analysed for B12-JR1-CBC presence using Tecan Infinite 200 Pro multiplate reader (Tecan Group,
Männedorf, Switzerland; λEx = 488 nm, λEm = 540 nm). The assay was performed three times in
duplicate and the results were presented as percentage of the control (RBC suspension the time of the
compound addition) that was arbitrarily set to 100%.
3.8. In Vivo Zebrafish Assays Toxicity
The toxicity evaluation of B12-JR1, B12-JR1-CBC and vitamin B12 in the zebrafish model was
carried out according to general rules of the OECD Guidelines for the Testing of Chemicals [62].
All experiments involving zebrafish were performed in compliance with the European directive
2010/63/EU and the ethical guidelines of the Guide for Care and Use of Laboratory Animals of the
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade. Embryos of wild
type zebrafish (Danio rerio, AB strain) were raised in a temperature- and light-controlled zebrafish
facility with 28 ◦C and standard 14:10-h light-dark photoperiod, and regularly fed with commercially
dry flake food (TetraMin™ flakes; Tetra Melle, Germany) twice a day and Artemia nauplii once daily.
Zebrafish embryos were produced by the pair-wise mating, collected and distributed into 24-well
plates containing 10 embryos per well and 1 mL embryos water (0.2 g L−1 of Instant Ocean® Salt in
distilled water), and raised at 28 ◦C. For assessing lethal and developmental toxicity, embryos staged
6 h post fertilization (hpf) were treated with four concentrations of B12-JR1 and vitamin B12 (50, 75, 100
and 150 µM) and four concentrations of B12-JR1-CBC (20, 25, 50 and 100 µM). DMSO (0.25% v/v) was
used as negative control. Experiments were performed three times using 30 embryos per concentration.
Apical endpoints for the toxicity evaluation (Table S1) were recorded at 24, 48, 72, 96 and 120 hpf using
an inverted microscope (CKX41; Olympus, Tokyo, Japan). Dead embryos were counted and discarded
every 24 h. At 120 hpf, embryos were inspected for heartbeat rate, anesthetized by addition of 0.1%
(w/v) tricaine solution (Sigma-Aldrich, St. Louis, MO, USA), photographed and killed by freezing
at −20 ◦C for ≥24 h. To analyse compound B12-JR1 and B12-JR1-CBC for possible hepatotoxic effect
in vivo, the transgenic Tg(fabp10:EGFP) zebrafish embryos with the fluorescently labelled liver were
exposed to the tested compounds at the 72 hpf stage, when the liver is fully functional, vascularized
and started metabolic transformation of absorbed compounds, assessing thus the effect of applied
compounds on the liver functioning. Embryos were exposed to the range of concentrations previously
determined that not affected embryos survival and development. Experiments were performed three
times using 5 embryos per concentration. The hepatotoxicity was determined according to the change
of liver area index compared to the control group, calculated as the ration between liver area and
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embryonic lateral area x 100%, as reported by Zhang et al. [63]. In addition, the liver colour and
retention of yolk were followed as the phenotypic signs of hepatotoxicity [64].
3.9. Distribution
To determine the distribution and the accumulation of B12-JR1 and B12-JR1-CBC through inner
organs, transgenic Tg(fabp:EGFP) zebrafish embryos were exposed to a non-toxic concentration of each
of the tested compounds (150 µM of B12-JR1 and 20 µM B12-JR1-CBC) in a period from 72 to 120 hpf (a
long exposure started when the liver became vascularized and capable to metabolize the absorbed
compounds) and 106 to 120 hpf (a shorter exposure time). To verify a preferential accumulation
of B12-JR1-CBC in the liver, the compound was applied intravenously (parenteral use) to zebrafish
embryos. The 106-hpf old embryos were anesthetized by addition of tricaine-methane sulfonate
(200 µg/mL, Sigma-Aldrich), and microinjected by a pneumatic picopump (PV820, World Precision
Instruments, USA) with 5 nL of B12-JR1-CBC (9.56 µg/nL per an embryo, corresponding to 20 µM dose
applied into embryo water). The treated embryos were analysed at 120 hpf by a fluorescent microscope
(Olympus BX51, Applied Imaging Corp., San Jose, CA, USA) upon Texas Red filter (an excitation max
596 nm, an emission max 620 nm) and Spectrum Green filter (an excitation max 497 nm, an emission
max 524 nm) to detect B12-JR1-CBC and the EGFP-labelled liver, respectively.
4. Conclusions
In summary, we have reported the synthesis of vitamin B12 derivatives designed for the delivery
the same antimalarial prodrug to both erythro- and hepatocytes. The drugs are released from the
Cbl scaffold with a 4-(4-ethynylphenyl)-triazole functionality. In this proof-of-concept study, the
chloroquine molecules we designed were equally active against chloroquine-resistant (CQR) and
chloroquine-sensitive (CQS) P. falciparum strains, and showed no toxicity in vitro and in vivo (zebrafish
model) no hepatotoxicity, no cardiotoxicity or developmental toxicity of the embryos. While we are
aware that this approach may not be cost effective for the treatment of a large number of individuals, it
may lead to development of antimalarial drugs of last resort or new organic drugs candidates based on
the triazole functionality we selected for this study.
Supplementary Materials: The following are available online. Figure S1: 500 MHz 1H-NMR of compound
JR1 (in DMF, * = solvent residual peak), Figure S2: 500 MHz 1H-NMR of compound JR2 (in DMF, * = solvent
residual peak), Figure S3: 500 MHz 1H-NMR of compound JR3 (in DMF, * = solvent residual peak), Figure S4:
500 MHz 1H-NMR of compound B12-F1 (in MeOD, * = solvent residual peak), Figure S5: 500 MHz 1H-NMR of
compound B12-F2 (in MeOD, * = solvent residual peak), Figure S6: 500 MHz 1H-NMR of compound B12-JR1
(in D2O, * = solvent residual peak), Figure S7: 500 MHz 1H-NMR of compound B12-JR2 (in D2O, * = solvent
residual peak), Figure S8: 500 MHz 1H-NMR of compound B12-JR3 (in D2O, * = solvent residual peak), Figure S9:
400 MHz 1H-NMR of compound N3-SN1 (in MeOD, * = solvent residual peak), Figure S10: 400 MHz 1H-NMR
of compound SN1 (in (CD3)2CO, * = solvent residual peak), Figure S11: 400 MHz 1H-NMR of compound
B12-SN1 (in D2O, * = solvent residual peak), Figure S12: DFT optimized structure of N-quinoline bound JR1
model with ferriprotoporphyrin IX, Figure S13: DFT optimized structure of N-triazole bound JR1 model with
ferriprotoporphyrin IX, Figure S14: DFT optimized structure of N-quinoline protonated JR1 model interacting with
ferriprotoporphyrin IX µ-oxo dimer, Figure S15: HR-ESI-MS spectrum (in MeOH) of compound JR1, Figure S16:
HR-ESI-MS spectrum (in MeOH) of compound JR2/3, Figure S17: HR-ESI-MS spectrum (in MeOH) of compound
B12-F1/2, Figure S18: HR-ESI-MS spectrum (in MeOH) of compound B12-JR1, Figure S19: HR-ESI-MS spectrum
(in MeOH) of compound B12-JR2/3, Figure S20: HR-ESI-MS spectrum (in MeOH) of compound B12-JR1-CBC,
Figure S21: Top: distribution of compound B12-JR1-CBC in suspension of washed red blood cells (RBC) over
time. RBC suspensions with (Sample) and without (Control) the molecule were incubated with 20 µM (final
concentration) of B12-JR1-CBC at 37 ◦C for 24 h in dark with shaking and at various time points aliquots were
centrifuged and the amount of fluorescence in the supernatant determined (λEx = 488 nm, λEm = 540 nm). Bottom:
fluorescence spectra of full smear blood control, Figure S22: Calculated IR spectrum of DFT optimized structure
(gas-phase) of the interaction of a protonated 4-(4-ethynylphenyl)-triazole functionalized quinoline drug model
with ferriprotoporphyrin IX µ-oxo dimer shown in Figure 5 of the manuscript. Note no negative frequencies
verifying a true minimum, Figure S23: Bio-distribution and accumulation of B12-JR1 and B12-JR1-CBC in the
120-hpf old transgenic Tg(fabp10:EGFP) zebrafish embryo with fluorescently labelled liver applied at different
developmental stages, Figure S24: HPLC traces of molecules prepared in this study, Table S1: Crystallographic
details of compound JR1, Table S2: Crystallographic details of compound B12-F2.
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